Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trialJun Tian, Ryan B. Corcoran, Mei Huang et al.|Nature Medicine|2023Cited by 197
SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patientsRyan B. Corcoran, Aparna R. Parikh, Marios Giannakis et al.|Annals of Oncology|2020Cited by 43
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survivalLeonie K. de Klerk, Adam J. Bass, Anuj Patel et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 30
FOLFOX plus ziv‐aflibercept or placebo in first‐line metastatic esophagogastric adenocarcinoma: A double‐blind, randomized, multicenter phase 2 trialJames M. Cleary, Peter C. Enzinger, Nora Horick et al.|Cancer|2019Cited by 24
Receipt and survival outcomes by age following second-line therapy for metastatic CRC (mCRC): Analysis of 5,289 patients from the ARCAD Clinical Trials Program.Nadine J. McCleary, Stuart M. Lichtman, William S. Harmsen et al.|Journal of Clinical Oncology|2020Cited by 1